Study 19: final overall survival in all patients and according to BRCAm... | Download Scientific Diagram
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial - The Lancet Oncology
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian... | Download Scientific Diagram
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer - Annals of Oncology
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial - The Lancet Oncology
SOLO-1 Phase 3 Trial Demonstrates LYNPARZA® (olaparib) Maintenance Therapy Cut the Risk of Disease Progression or Death by 70 Percent in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian Cancer | Business Wire
JCM | Free Full-Text | Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study | HTML
SGO on Twitter: "Olaparib maintenance therapy improves overall survival in recurrent #ovariancancer - important update of the SOLO2 trial at #ASCO20 #SGOatASCO #gyncsm https://t.co/xX2D6nyErE" / Twitter
18 Efficacy of maintenance olaparib plus bevacizumab by biomarker status in clinical higher- and lower-risk patients with newly diagnosed, advanced ovarian cancer in the PAOLA-1 trial | International Journal of Gynecologic Cancer
Olaparib Maintenance Reduces the Risk of Recurrence in Newly
Olaparib maintenance confers durable PFS benefit in advanced BRCA -mutated ovarian cancer
Olaparib Maintenance Therapy Delays Ovarian Cancer Progression - NCI
PARP inhibitor (olaparib) dramaticalyl extends progression free survival in 1L Maintenance BRCAm ovarian cancer data. Hazard ratio = 0.30. : r/medicine
Olaparib for Metastatic Breast Cancer | NEJM Resident 360 <meta property="twitter:image" content="https://resident360files.nejm.org/image/upload/c_fit,f_auto,h_120,w_120/v1538599218/u8buf4o8mgdxgmfcczjk.png" /> <meta property="og:image" content="https ...
Lynparza extended survival of ovarian cancer patients' < Pharma < 기사본문 - KBR
SOLO-2: Overall Survival Data on Olaparib for Relapsed, BRCA-Mutated Ovarian Cancer
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial - The Lancet Oncology
Use of PARP inhibitors in ovarian cancer | Cancer World Archive
Use of PARP inhibitors in ovarian cancer | Cancer World Archive
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer | NEJM
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer - Annals of Oncology
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial - Gynecologic Oncology
Efficacy of LYNPARZA® (olaparib) from Study 19
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy | British Journal of Cancer
PARP inhibitors in ovarian cancer - Cancer Treatment Reviews
Study 19: final overall survival in all patients and according to BRCAm... | Download Scientific Diagram
LYNPARZA® (olaparib) First-Line Maintenance Therapy Nearly Doubled the Time Without Disease Progression or Death in Phase 3 POLO Trial for Patients with Germline BRCA-Mutated Metastatic Pancreatic Cancer | BioSpace
